D.C.-Based 60 Degrees Pharmaceuticals Sets January 2027 Readout for Babesiosis Study, Plans FDA Pre-sNDA Meeting
60 Degrees Pharmaceuticals, a Washington, D.C.-based company developing medicines for vector-borne disease, announced on October 6, 2026 that it will conclude enrollment in its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis at 30 patients. The company plans to unblind the study and report primary and secondary endpoint results in January 2027, […]